Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): Recent advances in drug delivery

Journal of Pharmaceutical Investigation

Volumn 43, Issue 5, 2013, Pages 353-362

  Yoon, Goo ^a   Park, Jin Woo ^a   Yoon, In Soo ^a  

^a Mokpo National University   (South Korea)

Author keywords

Drug delivery; Nanostructured lipid carriers (NLCs); Solid lipid nanoparticles (SLNs); Solid lipid based nanoparticles (SLBNs)

Indexed keywords

AMPHOTERICIN B; APOMORPHINE; BUSPIRONE; CARVEDILOL; CELECOXIB; CYCLOSPORIN A; CYPROTERONE; DAUNORUBICIN; DIAZEMUL; DIAZEPAM; DIGOXIN; DOXORUBICIN; DRUG CARRIER; INSULIN; KETOPROFEN; METHOTREXATE; MEVINOLIN; NANOSTRUCTURED LIPID CARRIER; PENTOXIFYLLINE; PRAZIQUANTEL; PROPOFOL; QUERCETIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VINPOCETIN;

ATOMIC FORCE MICROSCOPY; COENZYME; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ELECTRON SPIN RESONANCE; MICROEMULSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 84884571428     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-013-0087-y     Document Type: Review

References (88)

1. Anton N, Benoit JP, Saulnier P (2008) Design and production of nanoparticles formulated from nano-emulsion templates--a review. J Control Release 128: 185-199.
2. Attama AA, Reichl S, Muller-Goymann CC (2009) Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 34: 698-705.
3. Aungst BJ (2000) Intestinal permeation enhancers. J Pharm Sci 89: 429-442.
4. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-tissue distribution. Pharmacol Res 43: 497-502.
5. Battaglia L, Gallarate M (2012) Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9: 497-508.
6. Braem C, Blaschke T, Panek-Minkin G, Herrmann W, Schlupp P, Paepenmuller T, Muller-Goyman C, Mehnert W, Bittl R, Schafer-Korting M, Kramer KD (2007) Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J Control Release 119: 128-135.
7. Bunjes H, Koch MH (2005) Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles. J Control Release 107: 229-243.
8. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238: 241-245.
9. Chan J, Maghraby GM, Craig JP, Alany RG (2007) Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 328: 65-71.
10. Charcosset C, El-Harati A, Fessi H (2005) Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release 108: 112-120.
11. Charman WN (2000) Lipids, lipophilic drugs, and oral drug delivery--some emerging concepts. J Pharm Sci 89: 967-978.
12. Chen CC, Tsai TH, Huang ZR, Fang JY (2010) Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74: 474-482.
13. Cirri M, Bragagni M, Mennini N, Mura P (2012) Development of a new delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for ketoprofen topical delivery. Eur J Pharm Biopharm 80: 46-53.
14. Das S, Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12: 62-76.
15. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV (2008) Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 70: 203-207.
16. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ (2009) Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5: 323-343.
17. Garcia-Fuentes M, Torres D, Martin-Pastor M, Alonso MJ (2004) Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles. Langmuir 20: 8839-8845.
18. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P (2004) PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm 57: 207-212.
19. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996-1003.
20. Gokce EH, Sandri G, Egrilmez S, Bonferoni MC, Guneri T, Caramella C (2009) Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res 34: 996-1003.
21. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB (2010) Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B 81: 412-421.
22. Griffin BT, O'Driscoll CM (2011) Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther Deliv 2: 1633-1653.
23. Han SY, Yoon I, Chin YW, Cho IW, Lee MG, Choi YH (2012) Pharmacokinetic interaction between metoprolol and SP-8203 in rats: competitive inhibition for the metabolism of metoprolol by SP-8203 via hepatic CYP2D subfamily. Xenobiotica 42: 1017-1027.
24. Harde H, Das M, Jain S (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 8: 1407-1424.
25. Harivardhan Reddy L, Sharma RK, Chuttani K, Mishra AK, Murthy RS (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 105: 185-198.
26. Holm R, Porter CJ, Mullertz A, Kristensen HG, Charman WN (2002) Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res 19: 1354-1361.
27. Hu FQ, Yuan H, Zhang HH, Fang M (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239: 121-128.
28. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S (2006) Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 314: 83-89.
29. Hu L, Jia H, Luo Z, Liu C, Xing Q (2010) Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 65: 110-113.
30. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J (2012) Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 20: 813-830.
31. Jaques PA, Kim CS (2000) Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhalation Toxicol 12: 715-731.
32. Joshi M, Patravale V (2008) Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346: 124-132.
33. Kakkar V, Singh S, Singla D, Kaur IP (2011) Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55: 495-503.
34. Kim JE, Cho HJ, Kim JS, Shim CK, Chung SJ, Oak MH, Yoon IS, Kim DD (2013) The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. Xenobiotica 43: 579-591.
35. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99: 259-269.
36. Kuchler S, Herrmann W, Panek-Minkin G, Blaschke T, Zoschke C, Kramer KD, Bittl R, Schafer-Korting M (2010) SLN for topical application in skin diseases--characterization of drug-carrier and carrier-target interactions. Int J Pharm 390: 225-233.
37. Lauweryns JM, Baert JH (1977) Alveolar clearance and the role of the pulmonary lymphatics. Am Rev Respir Dis 115: 625-683.
38. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009a) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133: 238-244.
39. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W (2009b) Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 379: 131-138.
40. Lin YK, Huang ZR, Zhuo RZ, Fang JY (2010) Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed 5: 117-128.
41. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z (2008) Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 356: 333-344.
42. Liu D, Liu Z, Wang L, Zhang C, Zhang N (2011) Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B 85: 262-269.
43. Maia CS, Mehnert W, Schafer-Korting M (2000) Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 196: 165-167.
44. Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107: 215-228.
45. Mehnert W, Mader K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
46. Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B (2013) Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci 102: 1994-2004.
47. Mukherjee B, Santra K, Pattnaik G, Ghosh S (2008) Preparation, characterization and in vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomed 3: 487-496.
48. Muller RH, Mader K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery--a review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
49. Muller RH, Radtke M, Wissing SA (2002a) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242: 121-128.
50. Muller RH, Radtke M, Wissing SA (2002b) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(Suppl 1): S131-S155.
51. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317: 82-89.
52. Muller RH, Petersen RD, Hommoss A, Pardeike J (2007) Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59: 522-530.
53. Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB (2008) Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68: 535-544.
54. Muller RH, Shegokar R, Keck CM (2011) 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 8: 207-227.
55. Obeidat WM, Schwabe K, Muller RH, Keck CM (2010) Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 76: 56-67.
56. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP (2009) Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5: 184-191.
57. Pandey R, Khuller GK (2005a) Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 55: 430-435.
58. Pandey R, Khuller GK (2005b) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85: 227-234.
59. Pardeike J, Hommoss A, Muller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366: 170-184.
60. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, Zimmer A (2011) Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 419: 329-338.
61. Patel M, Souto EB, Singh KK (2013) Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 10: 889-905.
62. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M (2010) Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 144: 233-241.
63. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26: 523-580.
64. Radomska-Soukharev A (2007) Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 59: 411-418.
65. Sahana B, Santra K, Basu S, Mukherjee B (2010) Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in vitro evaluation. Int J Nanomed 5: 621-630.
66. Sanjula B, Shah FM, Javed A, Alka A (2009) Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 17: 249-256.
67. Schafer-Korting M, Mehnert W, Korting HC (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59: 427-443.
68. Schubert MA, Muller-Goymann CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-131.
69. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ (2003) Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253: 23-38.
70. Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ (2008) Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers. Curr Drug Deliv 5: 324-331.
71. Souto EB, Mehnert W, Muller RH (2006) Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23: 417-433.
72. Stecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD, Schafer-Korting M (2007) Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 24: 991-1000.
73. Teeranachaideekul V, Souto EB, Junyaprasert VB, Muller RH (2007) Cetyl palmitate-based NLC for topical delivery of coenzyme Q(10)--development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 67: 141-148.
74. Trotta M, Debernardi F, Caputo O (2003) Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 257: 153-160.
75. Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, Tsai YH (2011) Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 100: 547-557.
76. Uner M, Yener G (2007) Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed 2: 289-300.
77. Varshosaz J, Minayian M, Moazen E (2010a) Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res 20: 115-123.
78. Varshosaz J, Tabbakhian M, Mohammadi MY (2010b) Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 20: 286-296.
79. Xiang QY, Wang MT, Chen F, Gong T, Jian YL, Zhang ZR, Huang Y (2007) Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 30: 519-525.
80. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z, Wang X, Zhou W (2010) Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine 5: 693-701.
81. Yang R, Gao R, Li F, He H, Tang X (2011) The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm 37: 139-148.
82. Ye J, Wang Q, Zhou X, Zhang N (2008) Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 352: 273-279.
83. Yoon IS, Choi MK, Kim JS, Shim CK, Chung SJ, Kim DD (2011) Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41: 243-251.
84. Yoon I, Han S, Choi YH, Kang HE, Cho HJ, Kim JS, Shim CK, Chung SJ, Chong S, Kim DD (2012) Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats. Xenobiotica 42: 1110-1119.
85. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ (2008) Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361: 239-244.
86. Zhang J, Fan Y, Smith E (2009) Experimental design for the optimization of lipid nanoparticles. J Pharm Sci 98: 1813-1819.
87. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, Pan YS, Tang X (2010) Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394: 179-185.
88. 1H NMR. Pharmazie 60: 508-513.